Roivant, Arbutus Stocks Soar on Moderna Settlement

Moderna Reaches $2.25B Patent Settlement

Moderna has agreed to a global settlement worth up to $2.25 billion with Roivant Sciences and Arbutus Biopharma. The agreement resolves patent infringement litigation concerning the lipid nanoparticle LNP delivery technology used in Moderna’s Spikevax COVID-19 vaccines. Following the news, Arbutus shares surged 24%, Roivant rose 6.5%, and Moderna gained 7% in after-hours trading.

Overview of the Agreement

The settlement includes an upfront payment of $950 million from Moderna to Genevant Sciences, a Roivant subsidiary, and Arbutus in July 2026. An additional $1.3 billion payment is contingent on a favorable appellate court ruling. If realized, this would become the largest disclosed patent settlement in the pharmaceutical industry. The deal grants Moderna a global non-exclusive license for the LNP technology for specific mRNA vaccine applications.

Impact on the Market

The resolution sent positive signals to investors, reflected in the sharp increase in stock prices for all involved companies. Roivant's board also approved an expanded $1 billion share repurchase program. The settlement resolves all legal actions between the parties over the Spikevax vaccine. However, Roivant noted that separate litigation against Pfizer and BioNTech regarding their Comirnaty vaccine remains ongoing.

Conclusion and Outlook

This landmark settlement concludes a significant legal battle in the biotech sector, providing clarity for Moderna and a substantial financial outcome for Roivant and Arbutus. Market attention will now likely shift to the continuing patent litigation involving other major vaccine manufacturers.

FAQ

Q: What was the core of the legal dispute?
A: The dispute was over the alleged infringement of patents for lipid nanoparticle LNP delivery technology used in Moderna's COVID-19 vaccine.

Q: How much is the total settlement worth?
A: The settlement is valued at up to $2.25 billion, consisting of a $950 million upfront payment and a $1.3 billion contingent payment.

Q: Does this settlement affect other vaccine makers?
A: No, this settlement is specific to Moderna. Roivant stated that litigation against Pfizer and BioNTech is still active.

Source: Investing.com